NEW YORK (GenomeWeb News) – A BGI-Shenzhen official has sent a letter to Complete Genomics CEO Cliff Reid refuting claims made by Illumina last week that were intended to cast doubt on BGI's ability to obtain regulatory clearance for their proposed merger and steer Complete Genomics toward a deal with Illumina instead.

BGI already has an agreement in place to acquire Complete Genomics for $3.15 per share, but it has yet to receive US antitrust clearance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.